BG104451A - Antiestrogen and progestin-containing peroral contraceptives - Google Patents

Antiestrogen and progestin-containing peroral contraceptives

Info

Publication number
BG104451A
BG104451A BG104451A BG10445100A BG104451A BG 104451 A BG104451 A BG 104451A BG 104451 A BG104451 A BG 104451A BG 10445100 A BG10445100 A BG 10445100A BG 104451 A BG104451 A BG 104451A
Authority
BG
Bulgaria
Prior art keywords
antiestrogen
progestin
peroral
contraceptives
neuterotrophic
Prior art date
Application number
BG104451A
Other languages
Bulgarian (bg)
English (en)
Inventor
Michael Gast
Christopher Miller
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of BG104451A publication Critical patent/BG104451A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG104451A 1997-11-06 2000-05-17 Antiestrogen and progestin-containing peroral contraceptives BG104451A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96508397A 1997-11-06 1997-11-06
PCT/US1998/023427 WO1999024027A2 (fr) 1997-11-06 1998-11-04 Contraceptifs oraux a base d'anti-oestrogenes associes a un progestatif

Publications (1)

Publication Number Publication Date
BG104451A true BG104451A (en) 2000-12-29

Family

ID=25509417

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104451A BG104451A (en) 1997-11-06 2000-05-17 Antiestrogen and progestin-containing peroral contraceptives

Country Status (28)

Country Link
EP (1) EP1051179B1 (fr)
JP (1) JP2001522798A (fr)
CN (1) CN1278732A (fr)
AR (1) AR016667A1 (fr)
AT (1) ATE304359T1 (fr)
AU (2) AU760540B2 (fr)
BG (1) BG104451A (fr)
BR (1) BR9813982A (fr)
CA (1) CA2307210A1 (fr)
CZ (1) CZ294155B6 (fr)
DE (1) DE69831605T2 (fr)
DK (1) DK1051179T3 (fr)
EA (1) EA200000492A1 (fr)
EE (1) EE04092B1 (fr)
ES (1) ES2246541T3 (fr)
GE (1) GEP20043290B (fr)
HR (1) HRP20000269A2 (fr)
HU (1) HUP0100293A3 (fr)
ID (1) ID24568A (fr)
IL (1) IL135621A0 (fr)
NO (1) NO20002167L (fr)
NZ (1) NZ503890A (fr)
PL (1) PL340623A1 (fr)
SK (1) SK6482000A3 (fr)
TR (1) TR200001268T2 (fr)
UA (1) UA68365C2 (fr)
WO (1) WO1999024027A2 (fr)
ZA (1) ZA9810136B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
EA005932B1 (ru) * 1998-05-15 2005-08-25 Уайт 2-фенил-1-[4-(2-аминоэтокси)бензил]индол в комбинации с эстрогенами
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
CA2382683A1 (fr) * 1999-09-13 2001-03-22 American Home Products Corporation Conjugues glucopyranosides de 2-(4-hydroxy-phenyl)-1-{4-(2-amin-1-yl-ethoxy)-benzyl|-1h-indol-5-ols
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
JP2005504032A (ja) 2001-07-31 2005-02-10 ファイザー・プロダクツ・インク エストロゲン・アゴニスト/アンタゴニスト、エストロゲン及びプロゲスチンの組み合わせを含む医薬組成物、キット及び方法
SI1809602T1 (sl) 2004-10-27 2009-04-30 Janssen Pharmaceutica Nv Indolni derivati, uporabni kot modulatorji progesteronskega receptorja
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
DE102008057230A1 (de) * 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
WO2013090829A1 (fr) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Modulateurs des récepteurs des œstrogènes et ses utilisations
KR20240142622A (ko) 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
LT3386500T (lt) 2015-12-09 2022-12-27 The Board Of Trustees Of The University Of Illinois Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454856B1 (fr) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
WO2018081168A2 (fr) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019006393A1 (fr) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Formes morphiques de git38 et leurs procédés de fabrication
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
KR20220034129A (ko) 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
KR20220119415A (ko) 2019-12-20 2022-08-29 씨4 테라퓨틱스, 인코포레이티드 Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물
TW202146412A (zh) 2020-03-05 2021-12-16 美商C4醫藥公司 用於標靶降解brd9之化合物
IL300397A (en) 2020-08-05 2023-04-01 C4 Therapeutics Inc Compounds for targeted knockdown of RET
MX2023014059A (es) 2021-06-08 2024-03-12 C4 Therapeutics Inc Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
WO2024030968A1 (fr) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Composés pour moduler la protéine ret
EP4611901A1 (fr) 2022-11-04 2025-09-10 Bristol-Myers Squibb Company Agents de dégradation de protéine ret-ldd
WO2024097980A1 (fr) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Inhibiteurs de protéines ret-ldd
EP4735452A2 (fr) 2023-06-30 2026-05-06 Merck Patent GmbH Composés hétérobifonctionnels pour la dégradation de la protéine kras

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716118B (en) * 1970-10-05 1972-05-31 Richardson Merrell Inc Contraception
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
PT802183E (pt) * 1996-04-19 2002-03-28 American Home Prod Agentes estrogenicos
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive

Also Published As

Publication number Publication date
CZ294155B6 (cs) 2004-10-13
NZ503890A (en) 2002-08-28
CN1278732A (zh) 2001-01-03
SK6482000A3 (en) 2000-11-07
AU760540B2 (en) 2003-05-15
DK1051179T3 (da) 2005-10-31
EE200000211A (et) 2001-04-16
WO1999024027A2 (fr) 1999-05-20
WO1999024027A3 (fr) 1999-07-15
ES2246541T3 (es) 2006-02-16
ID24568A (id) 2000-07-27
EA200000492A1 (ru) 2000-10-30
GEP20043290B (en) 2004-07-26
EP1051179A2 (fr) 2000-11-15
HRP20000269A2 (en) 2000-12-31
AR016667A1 (es) 2001-07-25
ATE304359T1 (de) 2005-09-15
IL135621A0 (en) 2001-05-20
AU1303199A (en) 1999-05-31
AU2003204896B2 (en) 2006-06-15
DE69831605T2 (de) 2006-06-14
EE04092B1 (et) 2003-08-15
HUP0100293A3 (en) 2002-12-28
JP2001522798A (ja) 2001-11-20
ZA9810136B (en) 2000-05-05
NO20002167L (no) 2000-06-28
HUP0100293A2 (hu) 2001-10-28
TR200001268T2 (tr) 2001-01-22
EP1051179B1 (fr) 2005-09-14
DE69831605D1 (de) 2005-10-20
CA2307210A1 (fr) 1999-05-20
UA68365C2 (en) 2004-08-16
BR9813982A (pt) 2000-09-26
NO20002167D0 (no) 2000-04-27
PL340623A1 (en) 2001-02-12
CZ20001661A3 (cs) 2000-12-13

Similar Documents

Publication Publication Date Title
BG104451A (en) Antiestrogen and progestin-containing peroral contraceptives
NZ330741A (en) Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen
AU560487B2 (en) Contraceptive comprising gestodene and ethinylestradiol
DK0491415T3 (da) Orale svangerskabsforebyggende midler med lavt østrogen
DE69118494D1 (de) Kontrazeptionsverfahren und Schema
FI922206A0 (fi) Osmotisk, oral doseringsform foer fertilitets kontroll.
DE69710896D1 (en) Progestogen-anti-progestogen therapien
LU90341I2 (fr) 75 Ug de désogestrel en l'absence éthinyl oestradiol (cerazette)
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
ATE91410T1 (de) Osmotische dosierungsform.
MX9707009A (es) Inyeccion de una vez al mes como un contraceptivo de base y para terapia de reemplazamiento hormonal para mujeres perimenopausicas y premenopausicas.
KR950024496U (ko) 여성용 콘돔(女性用 condom)